Rick Miller
Analyst, Cantor Fitzgerald
Replay available
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings conference call, held 2026-02-12. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Joshua Higa
Vice President of Investor Relations
June Lee
Analyst, Truist Securities
Luca Issy
Analyst, RBC Capital Markets
Steven Ionov
Analyst, TD Cowen
Tara Ahmad
Analyst, Bank of America
Allison Bratzel
Analyst, Piper Sandler
Sammy Corwin
Analyst, William Blair
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Ultragenyx Pharmaceutical Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.136 Good afternoon, and welcome to the Ultragenyx fourth quarter and full year 2025 financial 00:00:05.136 -- 00:00:10.441 results conference call. At this time, all participants are in a listen-only mode. 00:00:10.441 -- 00:00:14.405 At the end of the prepared remarks, you will have an opportunity to ask questions during 00:00:14.405 -- 00:00:19.610 the Q&A portion of the call. It is now my pleasure to turn the call to Joshua Higa, Vice 00:00:19.610 -- 00:00:22.571 President of Investor Relations. 00:00:22.814 -- 00:00:27.058 Thank you. We've issued a press release detailing our financial results, which you can 00:00:27.058 -- 00:00:30.018 find on our website at Ultragenyx.com. 00:00:30.018 -- 00:00:34.705 Joining me on this call are Emil Kakas, Chief Executive Officer and President, Howard 00:00:34.705 -- 00:00:39.713 Horn, Chief Financial Officer, Eric Harris, Chief Commercial Officer, and 00:00:39.713 -- 00:00:44.281 Eric Cromdes, Chief Medical Officer. I'd like to remind everyone that during today's 00:00:44.281 -- 00:00:47.265 call, we will be making forward-looking statements. 00:00:47.265 -- 00:00:51.171 These statements are subject to certain risks and uncertainties, and our actual results 00:00:51.171 -- 00:00:56.380 may differ materially. Please refer to the risk factors discussed in our latest SEC filings. 00:00:56.380 -- 00:00:59.682 I'll now turn the call over to Emil. 00:00:59.802 -- 00:01:01.884 Thanks, Josh, and good afternoon, everyone. 00:01:01.884 -- 00:01:03.565 2026 00:01:03.565 -- 00:01:07.669 is poised to be a significant year for the company as we reach key inflection points 00:01:07.669 -- 00:01:10.331 across multiple programs. 00:01:10.331 -- 00:01:15.335 This includes two potential approvals in MPS3A or Sanf...